$0.37
(Market cap
$1,460 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
12.9
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-6.6
-
Debt to Equity
0.3
-
Book Value
$--
-
EPS
$-2
-
Face value
--
-
Shares outstanding
97,219,193
7 Years Aggregate
CFO
$-185.63 Mln
EBITDA
$-291.57 Mln
Net Profit
$-273.50 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Mind Medicine Inc (MNMD)
| 17.6 | 13.5 | 29.7 | 85.1 | 60.8 | -23.5 | -- |
|
BSE Sensex*
| -11.2 | -4.2 | -10.2 | -8.7 | 7.0 | 8.4 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Mind Medicine Inc (MNMD)
| 92.4 | 66.4 | -89.4 | -54.8 | 573.7 | 26.9 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Mind Medicine Inc (MNMD)
|
15.8 | 1,460.2 | 0.0 | -168.1 | -- | -95.1 | -- | 12.9 |
| 75.0 | 758.2 | 0.0 | -19.8 | -- | -28.1 | -- | 12.8 | |
| 5.2 | 413.1 | 0.0 | -131.6 | -- | -61.8 | -- | 1.0 | |
| 9.6 | 5.8 | 14.5 | -4.4 | -28.0 | -11.8 | -- | 0.3 | |
| 0.8 | 98.7 | 0.0 | -31.3 | -- | -- | -- | 1,055.0 |
Shareholding Pattern
View DetailsAbout Mind Medicine Inc (MNMD)
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety... disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. Read more
-
CEO & Director
Mr. Robert Barrow
-
CEO & Director
Mr. Robert Barrow
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Mind Medicine Inc (MNMD)
What is the current share price of Mind Medicine Inc (MNMD) Today?
The share price of Mind Medicine Inc (MNMD) is $15.75 (NASDAQ) as of 13-Feb-2026 09:30 EDT. Mind Medicine Inc (MNMD) has given a return of 60.77% in the last 3 years.
What is the current PB & PE ratio of Mind Medicine Inc (MNMD)?
Since, TTM earnings of Mind Medicine Inc (MNMD) is negative, P/E ratio is not available.
The P/B ratio of Mind Medicine Inc (MNMD) is 12.91 times as on 13-Feb-2026, a 321 premium to its peers’ median range of 3.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-5.38
|
2.42
|
|
2023
|
-1.54
|
1.89
|
|
2022
|
-1.47
|
0.55
|
|
2021
|
-0.42
|
0.26
|
|
2020
|
-2.32
|
1.04
|
What is the 52 Week High and Low of Mind Medicine Inc (MNMD)?
The 52-week high and low of Mind Medicine Inc (MNMD) are Rs 16.65 and Rs 4.70 as of 19-May-2026.
What is the market cap of Mind Medicine Inc (MNMD)?
Mind Medicine Inc (MNMD) has a market capitalisation of $ 1,460 Mln as on 13-Feb-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Mind Medicine Inc (MNMD)?
Before investing in Mind Medicine Inc (MNMD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.